The goal of this observational study is to compare severity and mortality rates of acute cerebral infarction(requiring thrombolysis or endovascular recanalization) depending on the type of oral antidiabetic drug taken before the onset of cerebral infarction. Researchers will compare the group that used DPP-4 inhibitors as anti-diabetic drugs before cerebral infarction and the group that did not use them to see the effect of DPP-4 inhibitors in reducing severity of cerebral infarction.
This is a retrospective study to see the effects of reducing the severity of cerebral infarction(requiring thrombolysis or endovascular recanalization) of DPP-4 inhibitors by comparing the survival rate after acute cerebral infarction hospitalization, discharge rate to home, and medical cost. A. Severity of cerebral infarction and poor prognosis is mainly associated with hyperglycemia caused by diabetes, which increases the Infarction volume and hemorrhagic trasformation. B. However, the effect of loergin blood glucose on reducing the Infarction volume and improving prognosis of cerebral infarction has not been proven. C. Preclinical studies have demonstrated a anti-stroke effect that reduces the Infarction volume using certain anti-diabetic drugs. D. Therefore, there is a possibility that certain anti-diabetic drugs may reduce the severity of cerebral infarction as a class effect in addition to the effect of blood sugar control. E. This is particularly likely to exist in the DPP-4 inhibitor family identified through preclinical studies.
Study Type
OBSERVATIONAL
Enrollment
22,119
The definition of antidiabetic drug use is defined as a case in which an antidiabetic drug was prescribed for at least 2 months before stroke and the duration of treatment for stroke coincided with the prescribed duration of the drug.
1-year survival rate
The survival rates of the DPP-4 inhibitor group and the non-use group are compared 1 year after the onset of severe stroke.
Time frame: Check the data one year after the onset of stroke.
90-day survival rate
The survival rates of the DPP-4 inhibitor group and the non-use group are compared 90-day after the onset of severe stroke.
Time frame: Check the data 90-day after the onset of stroke.
re-hospitalization
The re-hospitalization rates of the DPP-4 inhibitor group and the non-use group are compared after the onset of severe stroke.
Time frame: 1 year after discharge the stroke treatment.
frequency of cerebral hemorrhage
The frequency of cerebral hemorrhage rates of the DPP-4 inhibitor group and the non-use group are compared after the onset of severe stroke.
Time frame: Hospitalization period and 1 year after discharge the stroke treatment.
Rate of Intensive care unit treatment
The Intensive care unit treatment rate of the DPP-4 inhibitor group and the non-use group are compared.
Time frame: Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
Duration of Intensive care unit
The duration of Intensive care unit of the DPP-4 inhibitor group and the non-use group are compared.
Time frame: Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
Rate of Stroke care unit treatment
The Stroke care unit treatment rate of the DPP-4 inhibitor group and the non-use group are compared.
Time frame: Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
Duration of Stroke care unit
The duration of Stroke care unit of the DPP-4 inhibitor group and the non-use group are compared.
Time frame: Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
tracheal intubation period
The tracheal intubation period of the DPP-4 inhibitor group and the non-use group are compared.
Time frame: Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
total hospitalization days
The total hospitalization days of the DPP-4 inhibitor group and the non-use group are compared.
Time frame: Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
medical expenses incurred at the time of hospitalization
The medical expenses incurred at the time of hospitalization of the DPP-4 inhibitor group and the non-use group are compared.
Time frame: Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
Home discharge rate
The Home discharge rate of the DPP-4 inhibitor group and the non-use group are compared.
Time frame: At the end of discharge from stroke treatment.
medical expenses after discharge from hospital
The medical expenses after discharge from hospital of the DPP-4 inhibitor group and the non-use group are compared.
Time frame: 1 year after discharge the stroke treatment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.